Introduction
O-Sulfated sialyl Lewis x structures play important roles in immune regulation, inammation, and cancer metastasis. 1 For example, 6-O-sulfo-sialyl Lewis x [6-O-sulfo-sLe x (1), Neu5Aca2-3Galb1-4(Fuca1-3)GlcNAc6SbOR] with an O-sulfate group at the carbon-6 of the N-acetylglucosamine (GlcNAc) residue (Fig. 1) is a well known ligand for L-selectin, a C-type (Ca 2+ -dependent) carbohydrate-binding protein (lectin) expressed broadly in most leukocytes in the blood. 1, 2 The interaction of 6-O-sulfo-sLe x (1) and L-selectin plays a critical role in lymphocyte homing to the peripheral lymph nodes 2 and in chronic inammation. 3 It has also been shown that human sialic acid-binding immunoglobulin-like lectin 4 Siglec-9 binds strongly 5,6 to 6-O-sulfo-sLe x , but the biological importance of this interaction is less well understood.
On the other hand, 6 0 -O-sulfo-sialyl Lewis x [6 0 -O-sulfo-sLe x (2), Neu5Aca2-3Gal6Sb1-4(Fuca1-3)GlcNAcbOR] with an Osulfate group at the carbon-6 of the galactose (Gal) residue ( Fig. 1) , 7 in addition to 6 0 -O-sulfo-sialyl-N-acetyllactosamine (6 0 -O-sulfo-sLacNAc, Neu5Aca2-3Gal6Sb1-4GlcNAcbOR), 8 was shown by glycan microarray studies to be a preferred glycan ligand for Siglec-8 and for its paralog mouse Siglec-F. 9 Siglec-8 is expressed in human allergic inammatory cells including eosinophils, mast cells, and basophils. 5, 10 Reducing the number of eosinophils, such as by soluble 6 0 -O-sulfo-sLe x synthetic polymer induced apoptosis, 11 has been suggested as an approach for asthma therapies. 12 Furthermore, 6 0 -O-sulfo-sLe x (2), in addition to 6 0 -O-sulfo-sLacNAc and 6 0 -O-sulfo-sialyl-lacto-N-neotetraose (6 0 -O-sulfo-sLNnT, Neu5Aca2-3Gal6Sb1-4GlcNAcb1-3Galb1-4GlcbOR), was shown to bind to langerin, 13 a C-type (Ca 2+ -dependent) lectin specic to Langerhans cells (immature antigen-presenting specic T cell immunity initiating dendritic cells of epidermis and mucosal tissues). 14 Although less efficient than Neu5Aca2-8Neu5Aca2-3LacNAc, both 6-O-sulfo-sLe x (1) and 6 0 -O-sulfo-sLe x (2) bound moderately to human Siglec-7. 5 Both are present in glycosylation-dependent cell adhesion molecule 1 (GlyCAM-1), an L-selectin ligand, 15 with 6 0 -O-sulfo-sLe x (2) as the major sulfated form. [16] [17] [18] Gal-6-Osulfotransferase and GlcNAc-6-O-sulfotransferase have been found to synergistically produce L-selectin ligands. This indicates either the potential synergistic involvement of both 6-Osulfo-sLe x (1) and 6 0 -O-sulfo-sLe x (2) or the involvement of 6 0 ,6di-O-sulfo-sLe x (3) ( Fig. 1) with O-sulfate groups at both the Gal and GlcNAc residues of sLe x in L-selectin-binding. 19 Human Siglec-7 and -8 have also been shown to bind more strongly to 6 0 ,6-di-O-sulfo-sLe x (3) than their mono-O-sulfated derivatives (1 and 2), while mouse Siglec-F has been shown to bind with similar strength to 6 0 ,6-di-O-sulfo-sLe x (3) and 6 0 -O-sulfo-sLe x (2). 6 The biological importance of O-sulfated sLe x structures makes them attractive synthetic targets. However, the structures of these compounds are relatively complex and include synthetically challenging a2-3-linked sialic acid, which suffers from low stereoselectivity and a high 2,3-elimination rate in chemical synthesis, [20] [21] [22] as well as the acid labile O-sulfate group. 23, 24 Chemically 20,25,26 or chemoenzymatically 27 synthesized Neu5Aca2-3Gal building blocks have been used as effective synthons for constructing more complex sialosides including sLe x and 6-O-sulfo-sLe x (1). 20 Several examples of the chemical 22, 28 or chemoenzymatic 29 synthesis of 6-O-sulfo-sLe x (1) as well as the chemical synthesis of 6 0 -O-sulfo-sLe x (2) 22,30,31 and 6 0 ,6-di-O-sulfo-sLe x (3) 32 have been reported. All these examples are, however, limited to compounds with the most abundant sialic acid form, N-acetylneuraminic acid (Neu5Ac). Despite the presence of more than 50 different sialic acid forms identied in nature, 33, 34 O-sulfated sLe x containing a sialic acid form other than Neu5Ac has not been synthesized.
We report here the development of efficient chemoenzymatic methods for the systematic synthesis of O-sulfated sLe x containing different sialic acid forms. The methods are demonstrated for representative examples of 6 0 -O-sulfo-sLe x (1), 6-Osulfo-sLe x (2) and/or 6 0 ,6-di-O-sulfo-sLe x (3) containing the most abundant Neu5Ac form and N-glycolylneuraminic acid (Neu5Gc), a sialic acid form commonly found in mammals other than humans, but which can be incorporated into the human glycome from dietary sources. 35 One efficient approach for the synthesis of O-sulfated sLe x with different sialic acid forms would be by direct sialylation of O-sulfated Le x using one-pot multienzyme (OPME) sialylation systems 36 containing an a2-3-sialyltransferase and a CMP-sialic acid synthetase (CSS), 37 with or without a sialic acid aldolase. 38 Such an approach has been successfully demonstrated for direct sialylation of non-sulfated Le x for the synthesis of sLe x containing a diverse array of naturally occurring and nonnatural sialic acid forms, using OPME systems containing a recombinant viral a2-3-sialyltransferase vST3Gal-I 39 or a bacterial multifunctional sialyltransferase mutant, Pasteurella (7) using an OPME b1-4-galactosyl activation and transfer system for the formation of 6-O-sulfo-LacNAcbProN 3 (4) followed by an OPME a1-3-fucosyl activation and transfer system for the formation of 6-O-sulfo-Le x bProN 3 (8) . Enzymes and abbreviations: SpGalK, Streptococcus pneumoniae TIGR4 galactokinase; 44 BLUSP, Bifidobacterium longum UDP-sugar pyrophosphorylase; 45 PmPpA, Pasteurella multocida inorganic pyrophosphorylase; 43 Hp4GalT, Helicobacter pylori b1-4-galactosyltransferase; 43 BfFKP, Bacteroides fragilis bifunctional L-fucokinase/ GDP-fucose pyrophosphorylase; 42 and Hp3FT, Helicobacter pylori a1-3-fucosyltransferase. 39 multocida a2-3-sialyltransferase 1 (PmST1) M144D. 40 The latter, with a high expression level (98 mg L -1 culture, >1000-fold higher than that of vST3Gal-I) and high promiscuity in tolerating different modications on the sialic acid in the substrates, is a superior choice for the synthesis. 40 However, it is not clear whether O-sulfated Le x structures could be used with PmST1 M144D as suitable acceptors in the OPME sialylation process to produce the desired O-sulfated sLe x with different sialic acid forms.
Results and discussion

Synthesis of O-sulfated disaccharides and O-sulfated Le x
In order to obtain O-sulfated Le x as potential acceptor substrates for PmST1 M144D, enzyme-catalyzed a1-3-fucosylation of the corresponding O-sulfated disaccharides was tested as a potential strategy. A one-pot three-enzyme (OP3E) a1-3fucosylation system (Scheme 1) 39, 41 containing Bacteroides fragilis bifunctional L-fucokinase/GDP-fucose pyrophosphorylase (BfFKP), 42 Pasteurella multocida inorganic pyrophosphorylase (PmPpA), 43 and Helicobacter pylori a1 6-O-Sulfo-LacNAcbProN 3 (4) was synthesized from 6-O-sulfo-GlcNAcbProN 3 (7) 43 using an improved OPME galactosyl activation and transfer system (Scheme 1) containing Streptococcus pneumoniae TIGR4 galactokinase (SpGalK), 44 Bidobacterium longum UDP-sugar pyrophosphorylase (BLUSP), 45 PmPpA, and a Helicobacter pylori b1-4-galactosyltransferase (Hp1-4GalT or Hp4GalT). 43 The EcGalK, BLUSP, and PmPpA allowed in situ formation of the donor substrate of Hp4GalT, uridine 5 0diphosphate-galactose (UDP-Gal), from monosaccharide galactose (Gal). 45 It was previously shown that Hp4GalT, but not Neisseria meningitidis b1-4-galactosyltransferase (NmLgtB), was able to use 6-O-sulfated GlcNAc and derivatives as acceptor substrates for the synthesis of b1-4-linked galactosides. 43 The activity of Hp4GalT in synthesizing 6-O-sulfo-LacNAcbProN 3 (4) was conrmed again here using the improved OPME approach. 45, 46 An excellent 89% yield was obtained, comparing favourably to the previous Hp4GalT-dependent OPME b1-4galactosylation approach (70% yield) which used Escherichia coli K-12 glucose-1-P uridylyltransferase (EcGalU), Escherichia coli UDP-galactose-4-epimerase (EcGalE), and PmPpA to produce UDP-Gal in situ from glucose-1-phosphate. 43 (8) was carried out using the OP3E a1-3-fucosyl activation and transfer system (Scheme 1). A yield of 70% was obtained. The combined sequential OPME b1-4-galactosylation and OPME a1-3-fucosylation (Scheme 1) was an effective approach for obtaining 6-O-sulfo-Le x bProN 3 (8) from a simple monosaccharide derivative 6-O-sulfo-GlcNAcbProN 3 (7) in an overall yield of 62%.
As Hp3FT was not able to use 6 0 -O-sulfo-LacNAcbProN 3 (5) or 6,6 0 -di-O-sulfo-LacNAcbProN 3 (6) efficiently as acceptors for fucosylation to obtain the desired Le x trisaccharides, the target trisaccharides 6 0 -O-sulfo-Le x bProNH 2 (9) and 6,6 0 -di-O-sulfo-Le x bProNH 2 (10) were chemically synthesized (Scheme 2) from monosaccharide synthons 11, 12, 27 13, and 14. 27 Notable features of the synthetic strategy include: (a) application of an efficient general protection strategy 47 for the synthesis of the two trisaccharides (i.e. similar protecting groups were used in the syntheses and the same reagents were used for their removal); (b) use of similar thioglycoside derivatives as glycosyl donors in all glycosylations; (c) high regio-and stereoselectivity in product formation; (d) one step removal of benzyl ethers and reduction of the azido group using 20% Pd(OH) 2 /C (Pearlman's catalyst) and H 2 . 48 More specically, for the synthesis of 9 and 10, two N-phthalimide glucosamine derivatives 11 and 12 selectively protected at C6 with benzyl and tert-butyldiphenylsilyl ether (TBDPS), respectively, were coupled stereoselectively with thioglycoside donor 13, which was selectively protected with TBDPS at C6, in the presence of N-iodosuccinimide (NIS) and trimethylsilyl triuoromethanesulfonate (TMSOTf) 49 in dichloromethane. Disaccharide derivatives 15 and 16 were obtained in 72% and 78% yields, respectively. The bulky N-phthalimido protecting group in acceptors 11 and 12 provides steric hindrance to the neighboring C-3 hydroxyl group and decreases the reactivity of the C-3 hydroxyl group. Therefore, glycosylation occurs regioselectively at the C-4 hydroxyl group. 27 Initial attempts to glycosylate acceptors 15 and 16 in dichloromethane with 1.2 equivalents of thiophenyl fucoside 14 produced trisaccharides in alpha and beta mixtures. In contrast, stereospecic formation of trisaccharides was achieved when a mixed solvent of diethylether and dichloromethane (1 : 1) 50,51 was employed. The reaction of acceptors 15 and 16 with 1.2 equivalents of fucosyl donor 14 produced compounds 17 and 18 in 68% and 65% yields, respectively. Compounds 17 and 18 were then subjected to a series of synthetic transformations: (a) conversion of the N-phthaloyl group to an acetamido group by removing the phthaloyl group using ethylenediamine, followed by N-and O-acetylation using acetic anhydride and pyridine; (b) HF-pyridine-mediated selective removal of the TBDPS group; 52 (c) O-sulfation of the primary hydroxyl group by SO 3 pyridine complex; 52, 53 
Enzymatic synthesis of O-sulfated sLe x
With chemoenzymatically synthesized 6-O-sulfo-Le x bProN 3 (8) as well as chemically synthesized 6 0 -O-sulfo-Le x bProNH 2 (9) and 6,6 0 -di-O-sulfo-Le x bProNH 2 (10) in hand, a one-pot two-enzyme (OP2E) sialylation system (Scheme 3) was used to test the tolerance of PmST1 M144D 40 for using these O-sulfated Le x compounds as potential acceptor substrates. PmST1 M144D was previously engineered by protein crystal structure-assisted design. It has 20-fold reduced CMP-sialic acid (donor) hydrolysis activity and signicantly (5588-fold) decreased a2-3-sialidase activity compared to the wild-type enzyme. It was used efficiently in a one-pot three-enzyme (OP3E) sialylation system for the synthesis of non-sulfated sLe x tetrasaccharides containing diverse sialic acid forms from Le x . 40 To our delight, PmST1 M144D also tolerated O-sulfated Le x containing Osulfate at C-6, C-6 0 , or both. In addition to N-acetylneuraminic acid (Neu5Ac), N-acetylneuraminic acid (Neu5Gc) was also successfully introduced to compounds 8-10. O-Sulfated sLe x tetrasaccharides 6-O-sulfo-Neu5Aca2-3Le x bProN 3 (1a, 80 mg, 85%), 6-O-sulfo-Neu5Gca2-3Le x bProN 3 (1b, 22 mg, 47%), 6 0 -Osulfo-Neu5Aca2-3Le x bProNH 2 (2a, 75 mg, 82%), 6 0 -O-sulfo-Neu5Aca2-3Le x bProNH 2 (2b, 45 mg, 60%), 6,6 0 -di-O-sulfo-Neu5Aca2-3Le x bProNH 2 (3a, 42 mg, 64%), and 6,6 0 -di-O-sulfo-Neu5Gca2-3Le x bProNH 2 (3b, 40 mg, 38%) were successfully obtained using this highly efficient one-pot two-enzyme system containing Neisseria meningitidis CMP-sialic acid (NmCSS) 37 and PmST1 M144D 40 from the corresponding acceptors 8-10 and Neu5Ac or Neu5Gc, respectively. In general, Neu5Gc was used less efficiently by the OPME sialylation system, leading to lower yields for 1b-3b (38-60%) compared to their Neu5Ac-counterparts 1a-3a (64-85%). O-Sulfated sLe x glycans with a propyl amine aglycone (compounds 2a, 3a, 2b and 3b) were found to be more challenging for column purication compared to the ones with a propyl azide aglycone (compounds 1a and 1b). When a desired sialic acid is readily available such as in the case presented here, a one-pot two-enzyme (OP2E) system is sufficient. When only the 6-carbon precursors of the desired sialic acid forms are available, the one-pot three-enzyme (OP3E) sialylation system including an aldolase in addition to NmCSS and PmST1 M144D 40 should be used.
Conclusions
In conclusion, we have successfully developed an efficient chemoenzymatic method for the systematic synthesis of synthetically challenging O-sulfated sLe x (1a-3a and 1b-3b) containing different sialic acid forms (Neu5Ac or Neu5Gc) by direct sialylation of the corresponding O-sulfated Le x structures 8-10 using an efficient one-pot two-enzyme (OP2E) system containing NmCSS and PmST1 M144D. The method can be extended to the synthesis of O-sulfated sLe x structures containing other sialic acid forms. We have also shown here that a relatively complex trisaccharide 6-O-sulfo-Le x bProN 3 (8) can be efficiently produced from a simple monosaccharide derivative 6-O-sulfo-GlcNAcbProN 3 (7) by a sequential OPME b1-4galactosylation and OPME a1-3-fucosylation process. PmST1 M144D has been demonstrated to be a powerful catalyst not only for synthesizing non-sulfated sLe x structures as shown previously, 40 but also for producing biologically important but difficult-to-obtain O-sulfated sLe x .
